Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as the company investigates four reported stroke events.

Shares in the NYSE-listed company dropped 2.8% at market open following the earnings, possibly a reflection of 2025 guidance.

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ('Johnson & Johnson') (NYSE:JNJ) concerning ...

J&J said it temporarily paused the use of the heart device, Varipulse, while it probes the cause of four reported “neurovascular events” in patients. J&J said the pause doesn’t affect ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Johnson & Johnson has announced a temporarily pause in the rollout of its Varipulse heart device in the United States as it investigates four reported stroke events. The decision comes ...

Timing is everything. Just days after confirming a pause in the U.S. rollout of its Varipulse pulsed field ablation (PFA) catheter, Johnson & Johnson’s electrophysiology program received an epic ...